Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Alternative Names: Antihemophilic factor [recombinant] PEGylated-aucl; BAY-949027; Damoctocog alfa pegol; Jivi; peg rFVIII; PEG rFVIII mutein; PEGylated B-Domain-Delted Recombinant rFVIII; PEGylated BDD-rFVIII; rFVIII glycopegylated

Latest Information Update: 14 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Amines; Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Propionic acids; Pyrrolidines; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A
  • Registered Haemorrhage

Most Recent Events

  • 21 May 2025 Bayer completes the phase III Alfa-PROTECT trial for Haemophilia A (Treatment-experienced, Inchildren) in Canada, Argentina, Brazil, Italy, Norway, Turkey, USA (IV,Infusion) (NCT05147662) (EudraCT2021-004858-30)
  • 19 May 2025 Registered for Haemophilia A (In children, Treatment-experienced) in USA (IV)
  • 27 Mar 2023 Registered for Haemophilia A (In adolescents, In children, In adults, Treatment-experienced) in Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top